Earl J Morris

Earl J Morris, Pharm.D., M.P.H., Ph.D.

Research Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6458
Business Email: earl.morris@ufl.edu

About Earl J Morris

Earl Morris, Pharm.D., M.P.H., Ph.D. is a Research Assistant Professor in the Department of Pharmaceutical Outcomes and Policy in the University of Florida College of Pharmacy. He received his Pharm.D. degree and M.P.H. degree from the University of Arkansas for Medical Sciences in 2019. He then received his Ph.D. in Pharmaceutical Sciences from the University of Florida College of Pharmacy in 2023. During his Ph.D. training, he was awarded an American Heart Association predoctoral fellowship. Dr. Morris is a pharmacoepidemiologist and pharmacist by training with a primary focus in leveraging rigorous pharmacoepidemiologic methods to answer clinical questions in the areas of geriatric pharmacotherapy and cardiorheumatology. His research aims to improve the identification and mitigation of adverse drug events in older adults and to better understand cardiovascular risk profiles among individuals with rheumatologic conditions. His work has been published in Pharmacoepidemiology and Drug Safety, the American Journal of Hypertension, Research in Social and Administrative Pharmacy, the Journal of the American Geriatrics Society, the American Journal of Pharmaceutical Education, the British Journal of Clinical Pharmacology, and more.

Teaching Profile

Courses Taught
2024-2025
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-6092-8906

Publications

2024
Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker-Loop Diuretic Prescribing Cascade.
Drugs & aging. 41(2):177-186 [DOI] 10.1007/s40266-023-01091-9. [PMID] 38252391.
2024
Mapping potentially inappropriate medications in older adults using the Anatomical Therapeutic Chemical (ATC) classification system
Journal of the American Geriatrics Society. 72(1):126-138 [DOI] 10.1111/jgs.18681.
2024
Skills laboratory faculty job satisfaction: Effects of high-contact teaching and the COVID-19 pandemic.
Currents in pharmacy teaching & learning. 16(3):160-166 [DOI] 10.1016/j.cptl.2023.12.012. [PMID] 38326192.
2024
Trends and Components of Thyroid Status Evaluation in Commercially Insured Adults in the United States, 2006-2020.
The Journal of clinical endocrinology and metabolism. 109(3):611-618 [DOI] 10.1210/clinem/dgad632. [PMID] 37889845.
2024
Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid–loop diuretic cascade
Journal of the American Geriatrics Society. 72(6):1728-1740 [DOI] 10.1111/jgs.18892. [PMID] 38547357.
2023
A lot in a little: Assessment of skills laboratory course structures and faculty workloads.
Currents in pharmacy teaching & learning. 15(9):801-807 [DOI] 10.1016/j.cptl.2023.07.017. [PMID] 37544785.
2023
Analysis of Prescriptions Dispensed After Death and Associated Medicare Spending Following Reimbursement Policy Changes in Medicare.
JAMA network open. 6(5) [DOI] 10.1001/jamanetworkopen.2023.14357. [PMID] 37227730.
2023
Continued potassium supplementation use following loop diuretic discontinuation in older adults: An evaluation of a prescribing cascade relic
Journal of the American Geriatrics Society. 71(2):505-515 [DOI] 10.1111/jgs.18103. [PMID] 36289555.
2023
Drivers of Individual and Regional Variation in CMS Hierarchical Condition Categories Among Florida Beneficiaries.
Risk management and healthcare policy. 16:1011-1022 [DOI] 10.2147/RMHP.S401474. [PMID] 37323190.
2023
High‐throughput screening for prescribing cascades among real world statin initiators
Pharmacoepidemiology and Drug Safety. 32(7):773-782 [DOI] 10.1002/pds.5607.
2023
Machine learning-based prediction models for home discharge in patients with COVID-19: Development and evaluation using electronic health records.
PloS one. 18(10) [DOI] 10.1371/journal.pone.0292888. [PMID] 37862334.
2023
Modifiable statin characteristics associated with potential statin‐related prescribing cascades
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 43(12):1307-1316 [DOI] 10.1002/phar.2883.
2022
Association between gabapentinoids and oedema treated with loop diuretics: A pooled sequence symmetry analysis from the USA and Denmark
British Journal of Clinical Pharmacology. 88(12):5269-5294 [DOI] 10.1111/bcp.15447.
2022
Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review
Research in Social and Administrative Pharmacy. 18(7):3079-3093 [DOI] 10.1016/j.sapharm.2021.08.003.
2022
Evaluation of a Beta-Blocker-Edema-Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis.
American journal of hypertension. 35(7):601-609 [DOI] 10.1093/ajh/hpac013. [PMID] 35106529.
2022
Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade.
Pharmacoepidemiology and drug safety. 31(1):72-81 [DOI] 10.1002/pds.5362. [PMID] 34553438.
2021
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.
Medical cannabis and cannabinoids. 4(1):21-42 [DOI] 10.1159/000515069. [PMID] 34676348.
2021
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
European Journal of Medicinal Chemistry. 224 [DOI] 10.1016/j.ejmech.2021.113675. [PMID] 34229108.
2021
Differences in Health-Related Quality of Life Among Adults with a Potential Dihydropyridine Calcium Channel Blocker-Loop Diuretic Prescribing Cascade.
Drugs & aging. 38(7):625-632 [DOI] 10.1007/s40266-021-00868-0. [PMID] 34095980.
2021
Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit.
Medical cannabis and cannabinoids. 4(2):121-124 [DOI] 10.1159/000517154. [PMID] 35224432.
2021
Use of negative controls in a prescription sequence symmetry analysis to reduce time‐varying bias
Pharmacoepidemiology and Drug Safety. 30(9):1192-1199 [DOI] 10.1002/pds.5293.

Grants

Jan 2023 – Aug 2023
Real-World Trajectories of Xanthine Oxidase Inhibitor Use and Downstream Cardiovascular Outcomes
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION

Education

Ph.D.
2023 · University of Florida
M.P.H.
2019 · University of Arkansas for Medical Sciences
Pharm.D.
2019 · University of Arkansas for Medical Sciences
B.A.
2015 · Arkansas State University
B.S.
2015 · Arkansas State University

Contact Details

Phones:
Business:
(352) 273-6458
Emails:
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
1225 CENTER DR
GAINESVILLE FL 32610